AstraZeneca Shares Slide After Heart Drug Trial Misses Primary Endpoint
() -- AstraZeneca's (AZN.L, AZN.ST) shares fell sharply on Thursday morning after the British drugmaker disclosed that a late-stage clinical trial for its heart disease drug candidate Wainua failed to meet its main goals. The Cardio-TTRansform phase 3 trial to evaluate Wainua, or eplontersen, as a potential additional